Drug Education Guide

Ipilimumab (Nurse)

CTLA-4 inhibitor Immunotherapy Monoclonal antibody

Ipilimumab (Nurse)

CTLA-4 inhibitor Immunotherapy Monoclonal antibody
Light Sensitive Fall Risk
Medication Basics

Drug Name

Ipilimumab (Brand names: Yervoy®)

Purpose / Indication

Used to treat certain cancers such as melanoma, renal cell carcinoma, colorectal cancer, lung cancer, mesothelioma, and other indications, often in combination with nivolumab. Verify indication, regimen, line of therapy, biomarker requirements, and institutional protocol before administration.

Dosage & Administration

Dose Schedule

Given as an intravenous infusion on a protocol-specific schedule. It may be given alone or in combination with nivolumab depending on diagnosis and treatment plan.

Route

IV (Intravenous)

Timing Considerations

Confirm treatment plan, cycle timing, combination agents, hold parameters, infusion duration, and any required pre-infusion assessments before administration.

Time of Day

Flexible

Special Instructions

Assess baseline symptoms, review labs, confirm consent, educate on immune-related or targeted-therapy toxicities, and follow institutional hypersensitivity/infusion reaction procedures.

Injection Techniques

Administer by IV infusion per institutional policy and current prescribing information. Do not administer IV push or bolus unless specifically supported by policy.

Mechanism of Action

Mechanism

Ipilimumab is a CTLA-4 blocking antibody that augments T-cell activation and proliferation. It has a notable risk of immune-mediated toxicities requiring prompt assessment and management.

13 More Sections — Members Only

Free membership unlocks the complete guide.

  • Side Effects
  • Drug Interactions
  • Contraindications
  • Monitoring
  • Adherence
  • + 8 more…
Was this guide helpful?